CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 81 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $389,000 | -80.1% | 39,550 | -79.8% | 0.01% | -81.5% |
| Q2 2020 | $1,951,000 | +12.6% | 195,997 | 0.0% | 0.03% | -3.6% |
| Q1 2020 | $1,733,000 | -3.9% | 195,997 | 0.0% | 0.03% | +55.6% |
| Q4 2019 | $1,804,000 | +54.6% | 195,997 | -1.2% | 0.02% | +38.5% |
| Q3 2019 | $1,167,000 | -51.0% | 198,441 | 0.0% | 0.01% | -50.0% |
| Q2 2019 | $2,382,000 | +137.3% | 198,441 | +138.7% | 0.03% | +136.4% |
| Q1 2019 | $1,004,000 | -3.8% | 83,122 | 0.0% | 0.01% | -15.4% |
| Q4 2018 | $1,044,000 | -15.8% | 83,122 | -0.5% | 0.01% | +8.3% |
| Q3 2018 | $1,240,000 | -11.5% | 83,547 | +0.4% | 0.01% | -14.3% |
| Q2 2018 | $1,401,000 | -26.1% | 83,247 | +0.5% | 0.01% | -26.3% |
| Q1 2018 | $1,896,000 | -17.4% | 82,803 | -6.7% | 0.02% | -13.6% |
| Q4 2017 | $2,295,000 | +70.5% | 88,705 | -2.8% | 0.02% | +100.0% |
| Q3 2017 | $1,346,000 | +4.0% | 91,262 | -1.6% | 0.01% | 0.0% |
| Q2 2017 | $1,294,000 | – | 92,787 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,253,000 | $7,097,000 | 0.26% |
| INGALLS & SNYDER LLC | 1,358,573 | $4,280,000 | 0.19% |
| RA Capital Management | 3,033,603 | $9,556,000 | 0.17% |
| Kensington Investment Counsel, LLC | 85,483 | $269,000 | 0.16% |
| Perceptive Advisors | 4,301,282 | $13,548,000 | 0.10% |
| NewEdge Wealth, LLC | 381,326 | $1,201,000 | 0.05% |
| Black Diamond Financial, LLC | 46,000 | $145,000 | 0.05% |
| Birchview Capital, LP | 20,000 | $63,000 | 0.04% |
| XTX Topco Ltd | 14,305 | $45,000 | 0.02% |
| Alyeska Investment Group, L.P. | 548,090 | $1,726,000 | 0.02% |